Study demonstrates dose-dependent relationship: each additional menopausal symptom associated with poorer cognitive function and increased behavioral changes in later life.
Higher genetic risk for schizophrenia correlated with reduced macular thickness, but the “variation is very unlikely to have an impact on visual acuity.”
The FDA has issued a safety alert on compounded topical finasteride products, citing adverse events and emphasizing the lack of regulatory approval or safety evaluation.